NCT02796118

Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects

ASP2151 Phase 1 Study - Multiple Oral Dosing Study in Healthy Non-elderly Male and Elderly Male Japanese Subjects-

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Male
• Age: 20 Years – 79 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate the safety and the pharmacokinetics of ASP2151 after multiple oral dosing of ASP2151 in healthy non-elderly male and elderly male Japanese subjects, and to compare the pharmacokinetics of ASP2151 in healthy non-elderly male and elderly male Japanese subjects.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	ASP2151	Oral
DRUG	Placebo	Oral

Timeline

• Start date: 2006-07-01
• Primary completion: 2006-10-01
• Completion: 2006-10-01
• First posted: 2016-06-10
• Last updated: 2016-08-29

Locations

1 site across 1 country: Japan